Abstract. Fusion of human myeloma cell line GM 4672 and tonsillar lymphoid cells from a normal donor resulted in 13 primary hybridomas, which produced IgM anti-single-stranded DNA (ssDNA) antibodies, as determined in enzyme-linked immunosorbent assay. Nine of these primary hybridomas have been cloned and a total of 34 clones were obtained. Supernatants of these cloned hybridomas were tested for binding to ssDNA, native DNA, RNA, low molecular weight supernatant DNA, polydeoxyguanylate-polydeoxycitidylate, polydeoxyadenylate-thymidylate sodium salt, and cardiolipin. Supernatants from all clones but one showed polyspecificity when reacting with the antigens tested. That the clones were true hybridomas rather than transformed lymphoid cells was evidenced by IgM anti-DNA antibody secretion, karyotype analysis, and HLA typing. These studies imply that immunoglobulin genes encoding for anti-DNA autoantibodies with a spectrum of nucleic acid specificities similar to systemic lupus erythematosus, exist among normal B lymphocytes.
Introduction
The presence of serum anti-DNA antibodies is characteristic of murine and human systemic lupus erythematosus (SLE)' (1, 2) . Such antibodies have been shown to participate in the immune complex nephritis associated with this disorder (3) . In addition, while antibodies to single-stranded DNA (ssDNA) also occur in SLE, they are frequently seen in several other conditions (4) , however, antibodies to double-stranded DNA are considered unique to SLE (5).
We and others have reported on the spontaneous occurrence of anti-DNA antibodies produced in vitro with the spleen cells of young preautoimmune New Zealand black/New Zealand white mice as well as some nonautoimmune normal strains (6) . In humans, the circulating lymphocytes of normal individuals may occasionally be stimulated to produce anti-DNA antibody in vitro, although a spontaneous in vitro anti-DNA antibody response has been noted with the circulating lymphocytes of SLE patients (7) . However, spontaneous in vitro production of anti-DNA antibodies is not restricted to cultures from SLE patients. We have been able to detect anti-DNA antibodies frequently in culture supernatants from nonstimulated tonsillar lymphoid cells of normal individuals (8) . This suggests that normal tonsillar lymphoid cells exist in a state of preactivation or differentiation that may be similar to that seen with the circulating B lymphocytes of SLE patients.
The fusion of normal tonsillar lymphocytes with myeloma cells to produce human-human anti-DNA hybridomas should provide a unique system for comparison with hybridomas of SLE origin such as those that have been recently reported by Shoenfeld et al. (9) . This paper describes the production of monoclonal anti-DNA antibodies derived from normal tonsillar lymphocytes. These monoclonal anti-nucleic acid antibodies showed binding characteristics similar to the anti-DNA antibodies present in SLE serum as well as the monoclonal antibodies obtained from SLE circulating lymphocytes (10) .
Methods
Preparation of donor's lymphoid cells. Palatine tonsils were obtained from a normal female donor (age 7). This patient's serum exhibited normal immunoglobulin levels, and lacked antibodies to ss-DNA and double-stranded DNA by enzyme-linked immunosorbent assay (ELISA). Tonsillar tissue was cut into small pieces, homogenized with a Dounce homogenizer in RPMI 1640, pH 7.4 (Gibco Laboratories, Grand Island, NY) and lymphoid cells were purified by centrifugation on a Ficoll-Hypaque density gradient (specific gravity, 1.08) (Ficoll 400, Pharmacia Fine Chemicals AB, Uppsala, Sweden; Hypaque, Winthrop Laboratories, Aurora, Ontario) according to Boyum (11) . Cells were washed three times in RPM! 1640 by resuspension after centrifugation at 300 g for 8 min. All centrifugation was done at 20'C. The final pellet was resuspended in serum-free medium (SFM) to the cell concentration needed for fusion. SFM contained RPMI 1640 supplemented with 1% 200 mM L-glutamine (Gibco Laboratories), 1% 10 mM sodium pyruvate (M.A. Bioproducts, Walkersville, MD), 1% 2.5 M N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (Hepes) (Gibco Laboratories), 1.25% of a solution containing 10,000 U/ml penicillin, 10,000 Mg/ml streptomycin (Gibco Laboratories), 0.5% 10 mM nonessential amino acids (M.A. Bioproducts), and 0.2% 50 mg/ml gentamycin (Schering Corp., Kenilworth, NJ).
Human myeloma cell line. The hypoxanthine phosphoribosyl transferase-deficient, hypoxanthine-aminopterine-thymidine (HAT) sensitive, IgG2K producer mutant cell Cell fusion. Fusion was performed according to the procedure described by Shoenfeld et al. (9) , with minor modifications as follows. Cells were mixed at ratios 1:1 and 5:1 (lymphoid cells/myeloma cells), co-pelleted by centrifugation (200 g, 10 min), and treated with 0.5 ml 44.4% polyethylene glycol 1450 (J. T. Baker Chemical Co., Phillipsburg, NY) in SFM. After gentle resuspension, the pelleted cells were spun down at 300 g for 3 min, resuspended in 10 ml SFM, and pelleted again at 200 g for 5 min. Finally, cells were resuspended in postfusion recovery medium (PFRM) and cultured for 24 h at 37°C in a humidified 5% CO2 atmosphere. PFRM consisted of RPMI 1640 supplemented with 1% 200 mM L-glutamine and 1% of a solution containing 10,000 U/ml penicillin, 10,000 Mg/ml streptomycin, 1% 100 mM sodium pyruvate, 0.5% 10 mM nonessential amino acids, 15% heat-inactivated FCS, and 0.2% 50 mg/ml gentamycin.
Postfusion hybridoma cultures. After 24 h of incubation in PFRM, cells were spun down at 200 g for 5 min and resuspended in HAT medium (12), supplemented with 5% NCTC 109 (M.A. Bioproducts).
Cells were dispensed at 4 X 101 cells/well in 2 ml on 24-well Costar trays (Costar, Data Packaging, Cambridge, MA) and at I X 105 cells/ well and 2 X 105 cells/well in 0.2 ml on 96-well Costar trays and cultured at 37°C in a humidified 5% CO2 atmosphere. One-half the HAT media was removed and replenished weekly. Positive growth was scored after 4 wk. 24-well tray supernatants were then screened for anti-DNA antibodies by using an ELISA, while 96-well tray hybridomas were transferred to 24-well trays for 7 d before screening for anti-DNA antibody. Anti-DNA antibody-producing hybridomas were cloned by limiting dilution at 2 cells/well in 0.2 ml of growth medium (GM); and the cells were left unfed for 4 wk. Growing cells were then transferred to 24-well trays and after 10 d were tested for anti-DNA antibody production. GM contained RPMI 1640 supplemented with 1% 200 mM L-glutamine, 1% 100 mM sodium pyruvate, 0.5% 10 mM nonessential amino acids, 5% NCTC 109, and 1% of a solution containing 10,000 U/ml penicillin, 10,000 Mg/ml streptomycin, and Mg/ml Colcemid (Gibco Laboratories) was added and cultures were incubated for 35 min. Cells were centrifuged at 200 g for 8 min and the pellet was resuspended in 4 ml of 75 mM potassium chloride. After incubation for 15 min at 37°C, cells were recentrifuged, resuspended in 4 ml of fixative (1:3 acetic acid/methanol), and left for 30 min at 4°C. Cells were then washed twice in fixative and resuspended in I ml of fixative. Two drops of the cell suspension were dispensed onto glass slides (ethanol washed and stored at minus 20°C) and allowed to air dry. Slides were washed in saline, stained with 4% Giemsa (Fisher Scientific Co., Fair Lawn, NJ) in 6 X 101 M phosphate buffer, pH 6.8, destained in distilled water and mounted with Permount (Fisher Scientific Co.). Slides were examined under the light microscope and 50 karyotypes were scored.
HLA typing. Actively proliferating cells were washed twice with GM, centrifuged for 8 min at 200 g and resuspended in GM at 2 X 106/ml. Terasaki (T-27) and Canadian Red Cross (NRLT 85-5) HLA typing trays were used for HLA typing by a microcytotoxicity assay as described by Terasaki et al. (15).
Results
Initial hybridization and antibody screening. After the myelomatonsillar lymphocyte fusion procedure 431 wells were seeded. Growth was observed in 110 wells (25.5%). An ssDNA ELISA assay system was used to screen for hybridomas producing anti-DNA antibody, and 13 of 110 wells (11.8%) were positive. Thus, positive wells for anti-ssDNA antibodies constituted 3% of the total 431 wells seeded. IgM and IgG levels were also quantitated by ELISA in hybridoma supernatants both positive and negative for anti-DNA antibodies. 85/110 hybridoma supernatants were available for testing, of which 13 were positive and 72 were negative for anti-DNA antibody. Both positive and negative hybridoma supernatants contained IgM; eight contained only IgG. None of the latter showed binding to DNA. The IgM levels of the positive hybridoma supernatants ranged from 0.5 to 8 pg/ml but the anti-DNA antibodynegative hybridoma supernatants contained <0.5 ;&g/ml. Despite the lower levels of IgM in the negative hybridomas, the lack of binding to DNA was not a reflection of lack of sensitivity of the ELISA assay, since positive hybridoma supernatants showed binding when these were diluted, well within the range of IgM levels observed in the anti-DNA antibody-negative supernatants. The overall yield of anti-ssDNA antibody producing hybridomas is a function of both the probability of obtaining successful fusion and the probability that successful fusion will lead to anti-ssDNA antibody production. Table I suggests that these variables may depend on both the concentration of cells used in postfusion cultures and on the ratio of lymphocyte/myeloma cells used in the fusion. For any given fusion ratio of cells the probability of finding hybridomas after the 24-h postfusion recovery and 4-wk culture period was higher when the cells were cultured at 4 X l10 cells/well than at 1 X 1Os cells/well; however, at the lower cell concentration (105) there was a greater probability of detecting hybridomas that produce anti-ssDNA antibodies. Both the probability of fusion and anti-ssDNA antibody production also appear to depend on lymphocyte/myeloma ratio with a ratio of 1:1 producing the highest values (87% for fusion; 21% for antissDNA antibody production). As indicated in Table I the overall yield of anti-ssDNA antibody-producing hybridomas (6.7%) was found with 1:1 cell ratio for fusion and a 4 X l0 cells/well for culturing.
The 13 positive supernatants for anti-ssDNA antibodies were also tested for binding to undenatured DNA. All except hybridomas KIM 3, KIM 8, and KIM 11 reacted with DNA ( Fig. 1) . Binding of supernatants to ssDNA was greater than to DNA except for KIM 12, which reacted equally well with both ssDNA and DNA.
Cloning ofprimary hybridomas. Cloning was successful in 9/13 primary hybridomas and yielded 34 clones. Four of these 13 primary hybridomas (KIM 2, KIM 3, KIM 6, and KIM 8) were not cloned. Fig. 2 shows the binding of the supernatants from 34 clones to poly(dA-dT), poly dG-poly dC, low molecularweight ( 150 base pairs) S/N DNA, RNA, cardiolipin, ssDNA, and DNA. All supernatants except KIM 1 1.1-KIM 11.8 showed polyspecificity in reacting with the antigens used. The different specificities of the antibodies produced by a given hybridoma culture can be characterized by the ratio of antibody reactivity with each antigen to reactivity with a reference antigen. The reference antigen was chosen as ssDNA, since it was universally reactive with all the hybridoma supernatants tested. Table II lists for all clones the ratio of antibody reactivity with each antigen to reactivity with ssDNA. From the data in Fig. 2 and Table II the relative reactivity of the clones for certain nucleic acid antigens allowed these clones to be separated into eight different groups. Table III Karyotyping of KIM 4 clones was also performed. Heterogeneity of the cells within the individual clones was observed with respect to the chromosomal number (Table IV) disorder. These observations are, to our knowledge, the first demonstration that hybridomas that synthesize anti-DNA autoantibodies can be obtained from a normal human lymphocyte source. Our observation that the tonsillar lymphocytes of most normal individuals (children and adults) have a high frequency of spontaneous anti-DNA antibody production in vitro predicted the successful fusion of such tonsillar lymphoid cells to the myeloma cell line and the production of a proportion of such hybridomas that produced anti-DNA antibody. The overall frequency of anti-DNA antibody-producing hybridomas (1 1.8%) under all culture and fusion conditions was similar to the frequency obtained by Shoenfeld et al. (10) , for anti-DNA antibody hybridomas using the same myeloma cell line and pokeweed mitogen-activated circulating SLE lymphocytes. In comparison, a higher frequency (21%) was obtained in the present studies, when a 1:1 ratio of myeloma/lymphocytes (unstimulated) was used, which possibly suggests the increased state of spontaneous activation of the lymphoid cells from this tonsillar source. These results also suggest that attention to fusion and culturing conditions might lead to an enhanced yield of specific hybridomas. We have made the assumption here that the tonsillar lymphoid cells in our studies were preactivated, perhaps by the influence of microbial agents in the tonsil on some previous occasion. It is conceivable that an even more efficient fusion of these cells might be obtained if additional pokeweed mitogen activation was used with this source of lymphoid cells. It is also possible that a higher yield of anti-DNA antibody-producing hybridomas could have been detected had we screened for nucleic acid antigens other than ssDNA, since some clones that bound strongly to cardiolipin, and poly dG * poly dC were barely reactive with ssDNA (KIM 12.5-12.9; 13.1).
The proof that the hybridomas that we have produced are indeed true hybrids is based on the observation that hybridoma culture supernatants bound to ssDNA and that this antibody was of the IgM class. Neither IgM nor anti-ssDNA antibodies were produced when the myeloma cell line GM 4672 was cultured alone. The possibility of culturing Epstein-Barr virus (EBV)-transformed tonsillar lymphocytes was excluded since the antibody-producing clones showed hyperdiploidy, a feature rarely present in EBV-transformed cells (16) . Stronger evidence against EBV transformation, and for true hybridoma production is the observation that the clones expressed not only the HLA antigens of the myeloma cell line but also additional antigens that presumably derived from the tonsillar donor, which indicating a dual origin of the hybrids. Further, the presence of complete killing with all anti-HLA reagents provides evidence (10, 17) . This chromosomal instability may account for the inability to clone some of our primary anti-DNA-producing hybridomas.
Similar ratios of ssDNA to DNA binding by supernatants from the primary hybridomas ( Fig. 1 ) and the clones of these hybridomas (Fig. 2) As presented in Fig. 2 , we have detected a broad spectrum of anti-DNA antibody specificities that resulted from the fusion of myeloma and tonsillar lymphoid cells from a normal donor.
A similar broad range of anti-DNA antibody specificities has been reported to exist in the serum of SLE patients as well as in the supernatants prepared from hybridomas of human and murine SLE origin (10, 18, 19 There is no example in the clones studied of anti-DNA antibody reacting towards low molecular weight S/N DNA alone. This may be an indication that immunogenic low molecular weight DNA (14) may be derived from nonimmunogenic high molecular weight DNA that contains the same determinants. An exception was noted for group 8 hybridomas, which show reactivity to S/N DNA but not to DNA, however, groups 7 and 8 are distinguished by the fact that they bind to RNA. This suggests that the primary epitope recognized by the antibodies in these groups may be RNA rather than DNA.
Since both poly (dA-dT) and poly dG * poly dC are expected by the Watson and Crick model to have the same double helical structure in the central region of the polymer, the general preference for poly dG*poly dC of antibodies from groups 4, 6, 7, and 8 may reflect a specificity for terminal ends of the nucleic acids and presumably terminal ends with guanine and/or cytosine.
Alternatively, it is possible that differing antibody specificities for the two synthetic polymers results from unique supercoiled structures dictated by the base composition. However, it is premature to state whether GC-rich regions are determinants for anti-DNA antibody production, and whether there is any significance for the development of autoimmune anti-DNA antibodies in either the enhanced thermodynamic stability of double strands rich in GC or the closeness of GCrich regions to the sites for initiation of replication of some viral strands. Some authors have suggested high GC content in DNA molecules found in DNA-anti-DNA antibody complexes (20) and in low molecular weight DNA fragments in lymphocytes of patients with SLE (21).
The present study implies that immunoglobulin genes coding for anti-DNA autoantibodies exist in the lymphocytes of normal individuals. These genes may have a common ancestral origin with anti-DNA antibody genes of SLE lymphocytes since these antibodies display similar antigenic binding specificities. These studies also provide base-line data on anti-DNA antibody production by recently constructed hybrids of a myeloma line and normal tonsillar lymphocytes. The spectrum of antibody specificities detected will be followed with time to determine the stability of the binding specificities. It will also be of interest to compare the anti-DNA antibody of SLE and normals through idiotype analysis with antiidiotype probes.
